A reply to "Who would benefit from average value-based pricing?"

Health Econ. 2021 Sep;30(9):2284-2286. doi: 10.1002/hec.4392. Epub 2021 Jul 9.

Authors

Rosella Levaggi¹, Paolo Pertile²

Affiliations

¹ Department of Economics and Management, University of Brescia, Brescia, Italy.
² Department of Economics, University of Verona, Verona, Italy.

PMID: 34245084
DOI: 10.1002/hec.4392

No abstract available

Keywords: contract theory; drug price; health economics; public economics; regulation.

MeSH terms

Costs and Cost Analysis
Drug Costs*
Economics, Pharmaceutical*
Humans